Вы находитесь на странице: 1из 11

Zika Virus VLP

(E, prM/M Proteins)


Description:

Creative Biostructure develops a safe, effective and


straightforward strategy to rapidly produce a Zika vaccine.
Our Zika Virus VLPs are composed of partially mature
particles containing Envelope (E), pre-Membrane (prM) and
Membrane (M). VLPs are produced in mammalian suspension
cell cultures offering a suitable system for rapid scale up of
manufacturing, without the risk of working with an infectious
agent. The lack of infectivity of the product eliminates the
need for chemical inactivation, which may compromise
vaccine efficacy and safety.
The particulate nature of the vaccine and the preservation
of a variety of conformational antigenic sites may even
render this vaccine efficacious in humans without using
adjuvant if its incorporation into a vaccine raises safety
concerns. In summary, the Zika VLP platform puts forward a
vaccine composition and production system ready for
clinical development of a safe and effective prophylactic
Zika vaccine, which is greatly needed to meet the
challenges imposed by the spread of the Zika epidemic.
Zika virus is an emerging disease that is spread by Aedes
mosquitoes. The virus was first isolated in Central Africa,
and has since spread to South Asia and more recently to
South America. It is a member of the flavivirus family, and
is structurally closely related to viruses such as Dengue
Fever Virus. Outbreaks were reported in Micronesia in 2007
and in Brazil in 2015, confirming at least 13 autochthonous
infections. The Zika virus outbreak in Brazil in 2016 has
gained world-wide attention, and has been linked to an
increasing number of microcephaly cases. In April 2016 the
Centers for Disease Control, in the USA, confirmed the link
between Zika virus infection of the fetus with microcephaly.
Clinically Zika virus can cause mild fever, rash, myalgia,
arthralgia and headaches, with one in four infected
individuals being asymptomatic. Due to similar
symptoms Zika virus infected individuals can easily be
mis-diagnosed as a dengue infection and vice-versa.
In addition, Zika virus has been implicated in causing
microcephaly through transmission in utero. There is
no vaccine or specific treatment available for Zika
virus.
Analysis of Zika virus sequences from infected
patients have shown that the strain circulating in
South America in 2015 is most closely related to the
strains circulating in Asia during outbreaks in 2007
and 2013-14. The South American strain was first
isolated and sequenced from a patient in Suriname,
and hence is known as the Zika Suriname strain.
Creative Biostructure provide highly purified Virus-
Like Particles (VLPs) products as antigens, produced
in a native format, mostly using a mammalian
expression system. Custom VLPs synthesis is also
offered presented as a cell lysate or a purified
antigen for use in vaccine development (including
use as an immunogen) and serological based
diagnostic assays.
Ordering Process
Thank you !
Excerpt from:
https://www.creative-biostructure.com/Zika-Virus-
VLP-E-prM-M-Proteins-581.htm

Вам также может понравиться